BHA veterinary grade API is composed primarily of 2-tert-butyl-4-hydroxyanisole and 3-tert-butyl-4-hydroxyanisole. The crystalline material shows a melting range of 48–63°C and low aqueous solubility. Pharmacopoeial assay and impurity controls align with USP-NF and Ph. Eur. monographs. In veterinary dosage forms, BHA functions as a chain-breaking phenolic antioxidant that terminates lipid peroxyl radicals in unsaturated feed-grade oils, vitamin premixes, and oxygen-sensitive active ingredients. Processing conditions determine whether BHA retains sufficient antioxidant capacity through the finished product shelf life.

BHA veterinary grade powder is first passed through a 500 µm screen and geometrically diluted with 10% of the total diluent mass in a bin blender before addition to a horizontal ribbon blender. Dry oral vitamin powders containing retinol, cholecalciferol, and tocopherol are protected at BHA loadings from 0.005% to 0.03% w/w. The lipophilic antioxidant partitions onto the surface of spray-dried fat-coated vitamins and reduces peroxide formation under accelerated storage at 40°C/75% RH. Bulk powder uniformity is verified by sampling 10 locations across the blender after 15 minutes of mixing. Analytical sieving uses USP <786>. Loss on drying is controlled by USP <731>. Water activity below 0.4 is maintained to limit BHA migration and caking. Packaging in foil-lined multi-wall paper sacks with nitrogen flush extends oxidation induction time. Production-scale ribbon blenders with 1,500 kg capacity require pre-blending of BHA with diluent because direct addition at 0.005% creates segregation and content uniformity failures in oxygen-sensitive products.

What Restricts BHA Loading in Aqueous Injectable Vehicles?

BHA has low solubility in water. Parenteral formulations therefore use a co-solvent stock of propylene glycol, ethanol, or benzyl alcohol to fully solubilise BHA before aqueous dilution. A stock concentration of 10 g/L BHA in propylene glycol is prepared under vacuum mixing at 35°C. The final injection vehicle typically retains 0.005% to 0.02% w/v BHA when the active pharmaceutical ingredient is prone to oxidative degradation. Nitrogen sparging maintains dissolved oxygen below 1 ppm during compounding. The solution is filled into amber Type I glass vials. Terminal sterilisation at 121°C for 15 minutes may cause limited BHA loss. Published data for this specific configuration is limited, so stability-indicating HPLC assay is required. Alkaline pH values above 8 promote phenolate ion formation and discoloration. The formulation pH is therefore buffered at 4.0–6.0 using citrate or acetate systems. Disodium edetate at 0.01% w/v suppresses metal-catalysed oxidation. Particulate matter is tested by USP <788>, bacterial endotoxins by USP <85>, and pH by USP <791>.

In liquid-filled hard gelatin capsule production, BHA is pre-dissolved in a mid-chain triglyceride or refined soybean oil fraction at 1–5% w/w before combining with oxidation-sensitive veterinary actives and emulsifiers. The oil phase is deaerated under vacuum at 40°C to lower dissolved oxygen below 2 ppm. Rotary die encapsulation and piston-filling machines require a Newtonian fill matrix. BHA addition does not increase viscosity above 400 mPa·s at 35°C when the carrier oil is maintained above its melting point. Gelatin shell moisture is held at 35–45% to prevent brittle fracture. BHA migration into the shell is limited by using the minimum effective concentration and by avoiding high ethanol levels in the fill. High-shear mixing of BHA with silica and lecithin before oil incorporation prevents localised oxidation hotspots. Capsule fill peroxide value is monitored by ISO 3960 and acid value by Ph. Eur. 2.5.1. Fill weight variation is checked by USP <905>. Storage in cold-form aluminium blisters reduces oxygen ingress to the fill matrix.

Compressed Tablet and Large-Animal Bolus Antioxidant Protection

For compressed veterinary tablets and large-animal boluses, BHA is dry-blended with microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium before lubrication. The antioxidant is used at 0.01% to 0.05% w/w of tablet mass. Tableting on a high-speed rotary press with 30–60 kN compression force generates die temperatures that must remain below 40°C. BHA melting begins near 48°C; localised heating above this threshold causes melt agglomeration and picking. Lubrication with magnesium stearate at 0.5% w/w is added last for 3–5 minutes to avoid over-lubrication. Tablet hardness is controlled at 80–120 N for small-animal tablets and 150–250 N for large-animal boluses. Friability is tested by USP <1216>. Disintegration is evaluated by USP <701>. BHA protects oxidation-sensitive vitamins and unsaturated fatty acids in direct-compression formulations. Wet granulation is used only when BHA is added after drying because aqueous granulation and tray drying at 60°C reduce antioxidant recovery. Final packaging in cold-form aluminium blisters lowers oxygen ingress and stabilises residual BHA content.

When BHA Is Introduced During Low-Moisture Fluid-Bed Granulation

Fluid-bed granulation of oxygen-sensitive veterinary granules uses BHA in the binder phase or as a dry top-spray after aqueous binder application. The inlet air temperature is set at 40–50°C while product temperature is kept at 28–35°C. BHA is dissolved in ethanol or propylene glycol at 5% w/w and sprayed through a top-spray nozzle at 0.8–1.2 bar atomising air pressure. Aqueous granulation is avoided when BHA is the only antioxidant because elevated moisture and temperature accelerate BHA loss. Final granule moisture is controlled at 1.5–2.5% by loss on drying. Dried granules are sieved through 1.0 mm and 0.25 mm screens to remove oversize and fines. Particle-size distribution is tested by USP <786>. The hydrophobic nature of BHA can cause static adhesion to filter bags. Anti-static polymer bags and grounded fluid-bed units reduce batch-to-batch variation. Granules are filled into sachets with desiccant to maintain water activity below 0.3. BHA recovery after fluid-bed drying is verified by HPLC because process loss varies with filter retention time.

Feed Premix Lines Apply BHA Post-Pellet to Restrict Thermal Loss

BHA is authorised in the European Union as feed additive E 320 under Regulation (EC) No 1831/2003 as a technological antioxidant. In medicated premix and compound feed production, direct addition of BHA to steam-conditioned mash is avoided. Conditioner temperatures of 80–90°C and pellet die retention times above 15 seconds cause sublimation and oxidative loss. Post-pellet application is used on a vacuum coater or continuous spray drum located after the dryer-cooler. BHA is dissolved in refined vegetable oil at 5–10% w/w and sprayed at 40–50°C onto cooled pellets. Target final BHA concentration in complete feed is 100–200 ppm on a dry-matter basis, but local registration dossiers must be checked for moisture-specific maximum limits. The spray system uses hydraulic nozzles with 60–100 µm droplets to achieve uniform coating. Peroxide value of the fat phase is monitored by ISO 3960. Finished feed is bagged with oxygen barrier liners. Published data for BHA retention in specific vacuum coater configurations is limited; recovery is verified by liquid chromatography in compliance with feed-additive monographs.

During manufacture of aqueous oral solutions for swine and poultry, BHA is added as a pre-dissolved stock in propylene glycol or glycerol formal. The final solution contains 0.005% to 0.02% w/v BHA and is buffered to pH 4.0–5.5 with citrate buffer. Low pH maintains BHA in its undissociated phenolic form and avoids phenolate-related discoloration. Disodium edetate at 0.01% w/v is included to chelate trace metal ions from water and equipment surfaces. The aqueous phase is sparged with nitrogen to maintain dissolved oxygen below 2 ppm. Flavoured veterinary syrups containing vitamin B-complex, iron, and unsaturated oils benefit from BHA protection. BHA crystallisation is minimised by keeping the co-solvent fraction above 20% v/v in the final formulation. Filling into amber polyethylene terephthalate bottles with induction-sealed closures restricts oxygen ingress. The solution is tested for pH by USP <791>, for microbial quality by USP <61> and USP <62>, and for delamination or turbidity by visual inspection under 2,000 lux illumination. Equipment contact parts are specified in 316L stainless steel to limit metal-catalysed oxidation.